Clinical trials recruiting in Trento, Italy

Phase breakdown

Conditions recruiting in Trento, Italy

Recruiting trials in Trento, Italy

• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
  NCT07005154 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
  NCT05646862 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
  NCT06312137 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
  NCT07284121 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
  NCT06629779 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
  NCT04916613 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Clinical-ultrasonographic Assessment of Pulmonary Emphysema
  NCT06533371 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
  NCT06473259 · Phase: Not specified · Ages: No age limits stated · Sex: Male
• EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase
  NCT06894173 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting
  NCT07583485 · Phase: Not specified · Ages: 18 Years and older · Sex: Female
• PRostate Cancer Plasma Integrative Multi-modal Evaluation
  NCT06981377 · Phase: Not specified · Ages: 18 Years and older · Sex: Male
• Prevention ICONA Dedicated Ensemble
  NCT07186244 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Protocol ITANET - Registry
  NCT04282083 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study on the Incidence of Malignant Neoplasms in Patients With Parkinson's Disease and Heterozygous Mutation of the GBA Gene
  NCT06814431 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• TMS-related Measures as Biomarker of Cognitive Impairment in PD
  NCT06835595 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
  NCT05950945 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database
  NCT07397585 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Trento, Italy?

21 recruiting trials have at least one study site in Trento, Italy.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.